biostudies-literatureUnknown22(1)Vernieri F<h4>Background</h4>Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway are effective and safe on migraine prevention. However, some drug agencies limited these treatments to one year due to their high costs. This study aimed at evaluating the effect of discontinuing mAbs anti-CGRP on monthly migraine days (MMDs) and disability in high-frequency episodic (HFEM) and chronic migraine (CM) patients.<h4>Methods</h4>This observational longitudinal cohort study was conducted at 10 Italian headache centres. Consecutive adult patients were followed-up for three months (F-UP1-3) after discontinuation of a one-year erenumab/galcanezumab treatment. The primary endpoint was the change in F-UP MMDs. Secondary endpoints included variation in pain intensity (Numerical RatinThe journal of headache and pain154https://www.ebi.ac.uk/biostudies/studies/S-EPMC8903705biostudies-literatureDiscontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.PMC8903705Rao RCevoli SBrunelli NMessina RFilippi MColombo BEgeo GTorelli PBarbanti PVernieri FQuintana SCosta CMd'Onofrio FAltamura CFavoni VfalseDiscontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.<h4>Background</h4>Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway are effective and safe on migraine prevention. However, some drug agencies limited these treatments to one year due to their high costs. This study aimed at evaluating the effect of discontinuing mAbs anti-CGRP on monthly migraine days (MMDs) and disability in high-frequency episodic (HFEM) and chronic migraine (CM) patients.<h4>Methods</h4>This observational longitudinal cohort study was conducted at 10 Italian headache centres. Consecutive adult patients were followed-up for three months (F-UP1-3) after discontinuation of a one-year erenumab/galcanezumab treatment. The primary endpoint was the change in F-UP MMDs. Secondary endpoints included variation in pain intensity (Numerical Ratin2021-01-01T00:00:00Z2021 Dec2025-04-04T12:44:47.011Z2025-04-04T12:44:47.011ZS-EPMC89037053492244410.1186/s10194-021-01363-y